ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2008
Neuroprotection for Huntington's disease: ready, set, slow.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Creatine Safety and Tolerability in Premanifest HD: PRECREST
Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study
Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability
Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD
Who cites it
17 citing papers in PubMed, 44 citations in OpenAlex.
- Role of aging‑related cytokines in neurodegenerative disease (Review).International journal of molecular medicine · 2026Review
- Refining the Language of Huntington's Disease Progression with the Huntington's Disease Integrated Staging System (HD-ISS).Journal of Huntington's disease · 2024Article
- RETRACTED: Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2022Review
- Zebrafish an experimental model of Huntington's disease: molecular aspects, therapeutic targets and current challenges.Molecular biology reports · 2021Review
- Impaired Cerebrovascular Reactivity in Huntington's Disease.Frontiers in physiology · 2021Article
- Targeting N17 domain as a potential therapeutic target for the treatment of Huntington disease: An opinion.EXCLI journal · 2021Article
- Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.Journal of Huntington's disease · 2018Review
- Joint reconstruction of white-matter pathways from longitudinal diffusion MRI data with anatomical priors.NeuroImage · 2016Article
- The Association of VDAC with Cell Viability of PC12 Model of Huntington's Disease.Frontiers in oncology · 2016Article
- HTRF analysis of soluble huntingtin in PHAROS PBMCs.Neurology · 2013Article
- The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models.Cell reports · 2012Article
- Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease.Cell reports · 2012Article
- Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year.Movement disorders : official journal of the Movement Disorder Society · 2011Article
- Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.Journal of cellular and molecular medicine · 2011Review
- Treatment of Essential Tremor: Are there Issues We are Overlooking?Frontiers in neurology · 2011Article
- Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study.Neurology · 2010Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The ultimate goal for Huntington's disease (HD) therapeutics is to develop disease-modifying neuroprotective therapies that can delay or prevent illness in those who are at genetic risk and can slow progression in those who are affected clinically. Neuroprotection is the preservation of neuronal structure, function, and viability, and neuroprotective therapy is thus targeted at the underlying pathology of HD, rather than at its specific symptoms. Preclinical target discovery research in HD is identifying numerous distinct targets, along with options for modulating them, with some proceeding into large-scale efficacy studies in early symptomatic HD subjects. The first pilot studies of neuroprotective compounds in premanifest HD are also soon to begin. This review discusses the opportunities for neuroprotection in HD, clinical methodology in premanifest and manifest HD, the clinical assessment of neuroprotection, molecular targets and therapeutic leads, and the current state of clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.